miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12

Retraction in: /10.3892/or.2021.8157

  • Authors:
    • Su Dong
    • Meishan Jin
    • Ye Li
    • Peiyou Ren
    • Jia Liu
  • View Affiliations

  • Published online on: February 1, 2016     https://doi.org/10.3892/or.2016.4604
  • Pages: 2151-2158
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Accumulating evidence has shown that aberrantly expressed microRNAs (miRs) are extensively involved in tumorigenesis. microRNA-137 (miR-137) has been reported as a tumor suppressor in various types of cancer. However, the biological function and underlying molecular mechanism of miR-137 in papillary thyroid carcinoma (PTC) remain largely unknown. Therefore, the present study aimed to investigate the expression pattern of miR-137 and its functional significance in PTC. Quantitative RT-PCR (qRT-PCR) assay showed that miR-137 expression was significantly downregulated in human PTC tissues, and its expression was significantly negatively correlated with tumor-node-metastasis (TNM) stage and lymph node metastasis. Functional assays showed that forced expression of miR-137 in PTC cells significantly inhibited proliferation, colony formation, migration and invasion in vitro. Importantly, on the basis of bioinformatic analysis and luciferase reporter assay, we found that miR-137 directly targeted the 3'-untranslated region (3'-UTR) of C-X-C motif chemokine 12 (also known as SDF-1) (CXCL12). qRT-PCR and western blot analysis further verified the results and demonstrated that miR-137 could downregulate CXCL12 expression in PTC cells. We also confirmed that CXCL12 expression was increased in PTC tissues and was inversely correlated with miR-137. In addition, our results also showed that downregulation of CXCL12 mimicked the effects of miR-137 overexpression, and upregulation of CXCL12 partially reversed the inhibitory effects of miR-137 in PTC cells. These results showed that miR-137 may function as a tumor suppressor in PTC by targeting CXCL12, suggesting that miR-137 may act as a potential target for PTC treatment.
View Figures
View References

Related Articles

Journal Cover

April-2016
Volume 35 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dong S, Jin M, Li Y, Ren P and Liu J: miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12 Retraction in /10.3892/or.2021.8157. Oncol Rep 35: 2151-2158, 2016
APA
Dong, S., Jin, M., Li, Y., Ren, P., & Liu, J. (2016). miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12 Retraction in /10.3892/or.2021.8157. Oncology Reports, 35, 2151-2158. https://doi.org/10.3892/or.2016.4604
MLA
Dong, S., Jin, M., Li, Y., Ren, P., Liu, J."miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12 Retraction in /10.3892/or.2021.8157". Oncology Reports 35.4 (2016): 2151-2158.
Chicago
Dong, S., Jin, M., Li, Y., Ren, P., Liu, J."miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12 Retraction in /10.3892/or.2021.8157". Oncology Reports 35, no. 4 (2016): 2151-2158. https://doi.org/10.3892/or.2016.4604